Sanofi has entered a two-year agreement with Massachusetts General Hospital (MGH) to further translational medicine research and develop new treatments for hematological malignancies and solid tumors. The collaboration will leverage scientific expertise from MGH and Sanofi and will include both preclinical and clinical translational research from proof-of-concept to tolerability and efficacy. The collaboration will initially involve two early development molecules with promising treatment appro...